Ascentage Pharma Group International (FRA:36X) Other Net Income (Loss) : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Other Net Income (Loss)?

Ascentage Pharma Group International's Other Net Income (Loss) for the six months ended in Dec. 2024 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Ascentage Pharma Group International's quarterly Other Net Income (Loss) increased from Dec. 2023 (€0.0 Mil) to Jun. 2024 (€0.0 Mil) but then declined from Jun. 2024 (€0.0 Mil) to Dec. 2024 (€0.0 Mil).

Ascentage Pharma Group International's annual Other Net Income (Loss) declined from Dec. 2022 (€-0.0 Mil) to Dec. 2023 (€-0.0 Mil) but then increased from Dec. 2023 (€-0.0 Mil) to Dec. 2024 (€0.0 Mil).

Ascentage Pharma Group International Other Net Income (Loss) Historical Data

The historical data trend for Ascentage Pharma Group International's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Other Net Income (Loss) Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial											-	-	-	-	-

Ascentage Pharma Group International Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

Ascentage Pharma Group International Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

AAPG:USA 06855:Hong Kong 36X0:Germany 36X0:Germany 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines